A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis.
- Citation:
- J Clin Oncol vol 28 (15s) abstr 8106
- Meeting Instance:
- ASCO 2010
- Year:
- 2010
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Preliminary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2054
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- V. A. Morrison J. L. Johnson S. Jung J. P. Leonard B. D. Cheson
- Networks:
- Study
- CALGB-50501
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: